Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunological Memory01:23

Immunological Memory

554
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
554
Active versus Passive Immunity01:31

Active versus Passive Immunity

590
Immunity, along with the ability to limit pathogen growth to prevent significant body tissue damage, can be gained either by (1) actively developing an immune response within the individual after exposure to a pathogen or after getting vaccinated or (2) passively transferring immune components from an immune individual to one who is nonimmune. Both these forms of immunity can be found naturally and in medical practices.
Active Immunity
Active immunity refers to the resistance one develops...
590
Cross-reactivity00:42

Cross-reactivity

31.0K
Overview
31.0K
Affinity and Avidity01:41

Affinity and Avidity

35.9K
Overview
35.9K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

969
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
969
Vaccinations01:51

Vaccinations

44.1K
Overview
44.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of care-pathways of older adults hospitalized for influenza-like illness before institutionalization: a French SNDS-based study.

BMC health services research·2026
Same author

Risk factors for acquisition of SARS-CoV-2 Omicron variant among a prospective cohort of French Healthcare Workers: impact of hybrid immunity.

Scientific reports·2026
Same author

Pregnant Women COVID-19 immunisation in 2026: evidence, uncertainty and priorities.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteers.

Scientific reports·2026
Same author

Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.

Vaccine·2026
Same author

RSV vaccination in immunocompromised adults.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026

Related Experiment Video

Updated: Jun 11, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

2.8K

Antibody Persistence and Risk of COVID-19 Infection: Insights from Modeling.

Laurent Coudeville1, Eleine Konate2, Tabassome Simon3

  • 1Global Medical, Vaccines, 69007 Sanofi Lyon, France.

Vaccines
|September 28, 2024
PubMed
Summary

The B.1.351 COVID-19 booster vaccine demonstrated superior neutralizing antibody (nAb) persistence and efficacy against SARS-CoV-2 infection compared to D614 and BNT162b2 formulations. Higher nAb levels correlated with a reduced risk of infection over six months.

Keywords:
COVID-19antibody persistencecorrelates of protectionneutralizing antibody titerstatistical modeling

More Related Videos

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

4.6K
Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
08:52

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

8.1K

Related Experiment Videos

Last Updated: Jun 11, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

2.8K
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

4.6K
Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
08:52

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

8.1K

Area of Science:

  • Immunology
  • Virology
  • Vaccinology

Background:

  • Exploratory analysis of the APHP-COVIBOOST trial (NCT05124171) investigating neutralizing antibody (nAb) evolution post-SARS-CoV-2 booster vaccination.
  • Focus on comparing three booster formulations: D614, B.1.351, and BNT162b2.

Purpose of the Study:

  • To statistically model the temporal dynamics of nAb titers following COVID-19 booster vaccination.
  • To assess the impact of nAb levels on SARS-CoV-2 infection risk.
  • To explore differences in nAb persistence and vaccine efficacy among distinct booster formulations.

Main Methods:

  • Measurement of nAb titers in 208 adults at 28 days, 3 months, and 6 months post-vaccination using microneutralization assays against Omicron subvariants.
  • Development of Bayesian statistical models to describe antibody decline, boosting upon breakthrough infection, and infection risk relative to nAb levels.
  • Cross-validation of model findings with a second validated microneutralization assay.

Main Results:

  • The B.1.351 vaccine exhibited significantly lower nAb titer decline compared to D614 and BNT162b2 formulations.
  • An inverse correlation was observed between nAb levels and the risk of SARS-CoV-2 infection.
  • The B.1.351 vaccine demonstrated a positive relative vaccine efficacy against any infection over 6 months (31% vs. BNT162b2, 21% vs. D614) against Omicron BA.1.

Conclusions:

  • Increasing nAb titers were associated with a reduced risk of infection across all vaccine formulations.
  • Statistical modeling predicted superior antibody persistence for the B.1.351 booster formulation compared to the others evaluated.